Jun. 13 at 1:00 PM
$IFRX A highlight of that May 28 PG PR: “no unexpected adverse events noted by the IDMC.”
That’s an extremely important fact, said with purpose, considering the comorbidities that often accompany PG patients, therefore immunocompromised to begin with, not the ideal population to be taking boxed warning meds such as adalimumab (the over
$200B earning, Humira).
Corticosteroid are effective in suppressing immune function, so fewer pro-inflammatory cytokines, fewer active neutrophils, but longer-term use adds risk of developing bacterial/fungal/viral infections, inducing insulin resistance, muscle wasting, weight gain, osteoporosis, hypertension, and psychosis.
This the best that science can offer these comorbid patients?
Here’s an interesting paper comparing steroid to cytokine blocker treatment in PG.
Check out the comorbidity levels of these patients: obesity, hypertension, and insulin resistance. So give em’ steroids noting the side effects?!
https://onlinelibrary.wiley.com/doi/10.1111/ajd.14532
